The growing burden of cancer, cardiovascular disorders, and neurological diseases is increasing demand for precise diagnostic and therapeutic technologies. Advances in nuclear medicine are enabling clinicians to detect diseases earlier and deliver more targeted treatment. Expanding radiopharmacy infrastructure and innovations in radiotracers are further strengthening adoption across healthcare systems.

The Radiopharmaceuticals Market was valued at US$9.07 billion in 2023 and is projected to reach US$26.51 billion by 2031, registering a CAGR of 14.4% during 2023–2031. Radiopharmaceuticals are increasingly being integrated into oncology, cardiology, neurology, and other specialties because they combine diagnostic imaging with targeted therapeutic capabilities. Growing investments in nuclear medicine, increasing clinical research, and the development of novel radioisotopes are expected to create significant opportunities for industry participants.

Get Sample PDF @ https://www.theinsightpartners.com/sample/TIPRE00003751

Rising Prevalence of Cancer and Chronic Diseases

The increasing prevalence of cancer and chronic diseases among aging populations is a major factor supporting industry growth. Radiopharmaceuticals enable physicians to visualize physiological processes and identify abnormalities through imaging techniques such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT). These technologies support early diagnosis, disease staging, treatment planning, and monitoring.

Oncology remains the leading application segment, accounting for 55.9% of the share in 2023. The growing use of fluorodeoxyglucose (FDG)-PET for cancer detection and monitoring has strengthened demand for diagnostic tracers. At the same time, therapeutic radiopharmaceuticals, including radioiodine-based treatments and emerging targeted radionuclide therapies, are expanding treatment options for patients with specific cancers.

Shift Toward Targeted Radiopharmaceutical Therapy

The transition toward personalized and targeted medicine is creating new growth opportunities. Radiopharmaceutical therapy delivers radioactive material directly to specific biological targets, allowing radiation to be concentrated near diseased cells while potentially reducing exposure to surrounding healthy tissue.

Targeted alpha therapy is attracting considerable attention because alpha-emitting radionuclides offer high linear energy transfer and a short tissue penetration range. Continued clinical research into alpha and beta emitters is expected to expand therapeutic applications. The growing number of clinical trials evaluating targeted radionuclide therapies is therefore emerging as an important growth driver.

The diagnostic segment is expected to register the fastest growth, with a projected CAGR of 14.8% during the forecast period. Increasing utilization of PET and SPECT imaging, combined with advancements in radiotracer development, is supporting this expansion.

Tc-99m Dominates Tracer Demand

Tracer technology remains central to the development of nuclear medicine. Tc-99m represented the largest tracer segment, accounting for 80.8% of the share in 2023. Its extensive use in diagnostic imaging across several clinical applications has established it as one of the most widely utilized radioisotopes.

Other tracers, including F-18 and Ga-68, are also gaining importance because of their applications in PET imaging and targeted diagnostic procedures. Developments in radiolabeling technologies and improved isotope production capabilities are expected to broaden the availability of advanced tracers.

Key companies and organizations operating across the industry include:

• General Electric Company
• Cardinal Health
• Bayer AG
• Novartis AG
• Curium
• Blue Earth Diagnostics
• Lantheus Medical Imaging, Inc.
• ABX Advanced Biochemical Compounds GmbH
• Bracco Imaging S.p.A.
• IBA Radiopharma Solutions
• Advanced Accelerator Applications S.A.
• Medi-Radiopharma
• Rotem Industries Ltd.
• Invicro LLC

Regional Growth and Emerging Opportunities

North America held the largest share, accounting for 44.3% in 2023. The region benefits from advanced healthcare infrastructure, a high prevalence of cancer and cardiovascular diseases, established nuclear medicine capabilities, and significant investment in radiopharmaceutical research. The US is expected to maintain a strong position, supported by product innovation, clinical research, and strategic collaborations among pharmaceutical companies, healthcare providers, and research institutions.

Asia Pacific represents another significant growth opportunity and is projected to register a CAGR of 14.9% during the forecast period. Countries such as China, Japan, and India are investing in PET and SPECT infrastructure while improving access to advanced diagnostic technologies. Growing healthcare expenditure and the rising disease burden are also encouraging companies to expand their presence across emerging economies.

Hospitals and clinics accounted for the largest end-user share at 68.2% in 2023. However, diagnostic centers are expected to record strong growth as demand for specialized nuclear imaging services increases.

Future Outlook

Increasing adoption of theranostics, targeted alpha and beta therapies, advanced PET and SPECT imaging, and personalized treatment approaches will remain key growth catalysts. Strategic collaborations between pharmaceutical companies, academic institutions, radiopharmacy providers, and healthcare organizations are likely to accelerate product development and commercialization. As radioisotope production capabilities improve and emerging economies expand nuclear medicine infrastructure, the industry is positioned for sustained growth through 2031.

Related Report:

1) Lyophilized Injectable Market Key Companies and SWOT Analysis by 2028

2) Pharmaceutical Intermediates Market Key Players and Forecast by 2028

3) Generic Injectables Market Growth and Forecast by 2028

About Us -

The Insight Partners provides comprehensive syndicated and tailored market research services in the healthcare, technology, and industrial domains. Renowned for delivering strategic intelligence and practical insights, the firm empowers businesses to remain competitive in ever-evolving global markets.

Contact Us:
Ankit Mathur | The Insight Partners
E-mail: ankit.mathur@theinsightpartners.com
Phone: +1-646-491-9876

Also Available in : Korean German Japanese French Chinese Italian Spanish